Business
Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis
Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company announcement replaces company announcement no. 10 published on 1 September 2025. The content of the announcement is unchanged. The correction solely consists of the announcement now being released under the correct category"Inside information" in accordance with the rules of Nasdaq Copenhagen. Copenhagen, Septemb
About this update from Pharma Equity Group A/s Class A
[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PTz7GpCf_hKeFTaw0Xo7Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis","length":176,"tagName":"p"},{"type":"text","content":"This company announcement replaces company announcement no. 10 published on 1 September 2025. The content of the announcement is unchanged. The correction solely consists of the announcement now being released under the correct category"Inside information" in accordance with the rules of Nasdaq Copenhagen.","length":330,"tagName":"p"},{"type":"text","content":"Copenhagen, September 01, 2025","length":30,"tagName":"p"},{"type":"text","content":"Company Announcement No. 10","length":27,"tagName":"p"},{"type":"text","content":"Reponex Pharmaceuticals A/S (Reponex), a subsidiary of Pharma Equity Group A/S (NASDAQ: PEG), today announced that it has received regulatory approval to initiate a pivotal Phase 2 clinical trial with its drug candidate RNX-011. The study will investigate the treatment of secondary peritonitis, a serious and life-threatening intra-abdominal infection with high mortality.","length":373,"tagName":"p"},{"type":"text","content":"The approval is a fundamental milestone for the company and a validation of the scientific strategy for RNX-011. The study addresses a critical unmet medical need in emergency abdominal surgery, where patient outcomes remain poor and where effective, local therapies to prevent serious complications are currently lacking.","length":322,"tagName":"p"},{"type":"text","content":"About the study: Designed to demonstrate commercial value","length":57,"tagName":"p"},{"type":"text","content":"The study is a randomized, placebo-controlled trial investigating a uniqu...